These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 30109794)

  • 1. Prompt Clinical Response to Secukinumab in Patients with Axial Spondyloarthritis: Real Life Observational Data from Three Italian Referral Centers.
    Gentileschi S; Vitale A; Rigante D; Lopalco G; Emmi G; Orlando I; Di Scala G; Sota J; Fabiani C; Frediani B; Galeazzi M; Lapadula G; Iannone F; Cantarini L
    Isr Med Assoc J; 2018 Jul; 20(7):438-441. PubMed ID: 30109794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis.
    Gentileschi S; Rigante D; Sota J; Lopalco G; Giannotta MG; Emmi G; Di Scala G; Iannone F; Fabiani C; Frediani B; Cantarini L
    Mediators Inflamm; 2020; 2020():6983272. PubMed ID: 32317863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validity and reliability of the Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in patients with axial spondyloarthritis (axSpA) in Singapore.
    Kwan YH; Tan JJ; Phang JK; Fong W; Lim KK; Koh HL; Lui NL; Tan CS; Østbye T; Thumboo J; Leung YY
    Int J Rheum Dis; 2019 Dec; 22(12):2206-2212. PubMed ID: 31721427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discriminant validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis: a cohort study.
    Kilic E; Kilic G; Akgul O; Ozgocmen S
    Rheumatol Int; 2015 Jun; 35(6):981-9. PubMed ID: 25366469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there any gender-specific difference in the cut-off values of ankylosing spondylitis disease activity score in patients with axial spondyloarthritis?
    Kilic G; Kilic E; Ozgocmen S
    Int J Rheum Dis; 2017 Sep; 20(9):1201-1211. PubMed ID: 27309497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Discriminative Values of the Bath Ankylosing Spondylitis Disease Activity Index, Ankylosing Spondylitis Disease Activity Score, C-Reactive Protein, and Erythrocyte Sedimentation Rate in Spondyloarthritis-Related Axial Arthritis.
    Tsang HHL; Chung HY
    J Clin Rheumatol; 2017 Aug; 23(5):267-272. PubMed ID: 28661926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis.
    Ciurea A; Scherer A; Weber U; Exer P; Bernhard J; Tamborrini G; Riek M; Müller RB; Weiss B; Nissen MJ; Kissling R; Michel BA; Finckh A;
    Ann Rheum Dis; 2016 Mar; 75(3):532-9. PubMed ID: 25667205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construct validity and responsiveness of the simplified version of Ankylosing Spondylitis Disease Activity Score (SASDAS) for the evaluation of disease activity in axial spondyloarthritis.
    Salaffi F; Ciapetti A; Carotti M; Gasparini S; Citera G; Gutierrez M
    Health Qual Life Outcomes; 2014 Aug; 12():129. PubMed ID: 25146299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cut-Offs for Disease Activity States in Axial Spondyloarthritis With Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on C-Reactive Protein and ASDAS Based on Erythrocyte Sedimentation Rate: Are They Interchangeable?
    Georgiadis S; Ørnbjerg LM; Michelsen B; Kvien TK; Di Giuseppe D; Wallman JK; Závada J; Provan SA; Kristianslund EK; Rodrigues AM; Santos MJ; Rotar Ž; Pirkmajer KP; Nordström D; Macfarlane GJ; Jones GT; van der Horst-Bruinsma I; Hellamand P; Østergaard M; Hetland ML
    J Rheumatol; 2024 Jul; 51(7):673-677. PubMed ID: 38621792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal Association Between Trabecular Bone Loss and Disease Activity in Axial Spondyloarthritis: A 4-year Prospective Study.
    Kang KY; Ju JH; Park SH; Hong YS
    J Rheumatol; 2020 Sep; 47(9):1330-1337. PubMed ID: 31732556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
    Pedersen SJ; Sørensen IJ; Hermann KG; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Johansen JS; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Hansen A; Ostergaard M
    Ann Rheum Dis; 2010 Jun; 69(6):1065-71. PubMed ID: 19740906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis.
    Levitova A; Hulejova H; Spiritovic M; Pavelka K; Senolt L; Husakova M
    Arthritis Res Ther; 2016 Nov; 18(1):275. PubMed ID: 27887637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance characteristics of the simplified version of ankylosing spondylitis disease activity score (SASDAS).
    Solmaz D; Yildirim T; Avci O; Tomas N; Akar S
    Clin Rheumatol; 2016 Jul; 35(7):1753-8. PubMed ID: 26670454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration.
    Michelsen B; Lindström U; Codreanu C; Ciurea A; Zavada J; Loft AG; Pombo-Suarez M; Onen F; Kvien TK; Rotar Z; Santos MJ; Iannone F; Hokkanen AM; Gudbjornsson B; Askling J; Ionescu R; Nissen MJ; Pavelka K; Sanchez-Piedra C; Akar S; Sexton J; Tomsic M; Santos H; Sebastiani M; Österlund J; Geirsson AJ; Macfarlane G; van der Horst-Bruinsma I; Georgiadis S; Brahe CH; Ørnbjerg LM; Hetland ML; Østergaard M
    RMD Open; 2020 Sep; 6(3):. PubMed ID: 32950963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Necrosis Factor-α Inhibition in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Treatment Response, Drug Survival, and Patient Outcome.
    Corli J; Flipo RM; Philippe P; Bera-Louville A; Béhal H; Wibaux C; Paccou J
    J Rheumatol; 2015 Dec; 42(12):2376-82. PubMed ID: 26568593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort.
    Ramiro S; van der Heijde D; van Tubergen A; Stolwijk C; Dougados M; van den Bosch F; Landewé R
    Ann Rheum Dis; 2014 Aug; 73(8):1455-61. PubMed ID: 24812292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of the Ankylosing Spondylitis Disease Activity Score based on a quick quantitative C-reactive protein assay in patients with axial spondyloarthritis.
    Proft F; Muche B; Spiller L; Rios Rodriguez V; Rademacher J; Weber AK; Lüders S; Protopopov M; Redeker I; Spiller I; Sieper J; Poddubnyy D
    Joint Bone Spine; 2020 Jan; 87(1):69-73. PubMed ID: 31369867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug Survival, Effectiveness and Safety of Secukinumab in Axial Spondyloarthritis up to 4 Years: A Real-Life Single Center Experience.
    Diaconu AD; Pomîrleanu C; Russu M; Strugariu G; Ancuța E; Ciortescu I; Bologa C; Morărașu BC; Constantin M; Ceasovschih A; Șorodoc V; Șorodoc L; Ancuța C
    J Pers Med; 2024 Apr; 14(4):. PubMed ID: 38673044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study.
    Nam B; Koo BS; Lee TH; Shin JH; Kim JJ; Lee S; Joo KB; Kim TH
    BMC Musculoskelet Disord; 2021 Feb; 22(1):140. PubMed ID: 33541326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construct validity of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) treatment target cut-offs in a BASDAI treat-to-target axial spondyloarthritis cohort: a cross-sectional study.
    Michielsens C; Bolhuis TE; van Gaalen FA; van den Hoogen F; Verhoef LM; den Broeder N; den Broeder AA
    Scand J Rheumatol; 2024 May; 53(3):180-187. PubMed ID: 37339375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.